108.2: 5-(2-chloro-3-methoxyphenyl)-3-((S)-2-methoxy-1-methylethyl)-1-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-1H-pyrimidine-2,4-dione (compound 108)
Similarly to example 13.4, starting from 450 mg (1.2 mmol) of [5-(2-chloro-3-methoxyphenyl)-3-((S)-2-methoxy-1-methylethyl)-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl]-acetic acid and 346 mg (1.4 mmol) of 3-piperidin-4-yl-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one (prepared as described in example 16.4), and after crystallization in ethyl acetate, 250 mg (35%) of 5-(2-chloro-3-methoxyphenyl)-3-((S)-2-methoxy-1-methylethyl)-1-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-1H-pyrimidine-2,4-dione is obtained in the form of a white solid with a melting point of 274Â° C.